A clinical-stage biotech building a family of RNA medicines through its PRISM platform, which uses chemical tweaks called stereopure chemistry to make drugs that can edit, silence, or splice genetic messages. Its experimental treatments target conditions including obesity, alpha-1 antitrypsin deficiency, and Huntington's disease. Founded in 2012 and first named Ontorii, the company's "Wave" name nods to the wave of RNA innovation, and it manufactures its own medicines at a plant in Lexington, Massachusetts.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: +9.14M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.